Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | GBA1 | P04062 | 4/20 | 0.49 |
| ▸ | GJB2 | P29033 | 1/20 | 0.47 |
| ▸ | LGALS8 | O00214 | 2/20 | 0.45 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.45 |
| ▸ | LGALS4 | P56470 | 2/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | FGF1 | P05230 | 3/20 | 0.41 |
| ▸ | FGF2 | P09038 | 3/20 | 0.41 |
| ▸ | VEGFA | P15692 | 3/20 | 0.41 |
| ▸ | HPSE | Q9Y251 | 3/20 | 0.41 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23113799 | 1.00 | MAPK1 (0.52) | MAPK1GBA1GJB2LGALS8LGALS3 | |
| SCHEMBL9547050 | 0.98 | MAPK1 (0.51) | MAPK1GBA1GJB2LGALS8LGALS3 | |
| SCHEMBL18733215 | 0.92 | MAPK1 (0.44) | MAPK1GBA1GJB2LGALS8LGALS3 | |
| SCHEMBL18030218 | 0.92 | MAPK1 (0.44) | MAPK1GBA1GJB2LGALS8LGALS3 | |
| SCHEMBL18333048 | 0.92 | MAPK1 (0.44) | MAPK1GBA1GJB2LGALS8LGALS3 | |
| SCHEMBL17300176 | 0.92 | MAPK1 (0.44) | MAPK1GBA1GJB2LGALS8LGALS3 | |
| SCHEMBL12819629 | 0.92 | MAPK1 (0.44) | MAPK1GBA1GJB2LGALS8LGALS3 | |
| SCHEMBL18733408 | 0.92 | MAPK1 (0.44) | MAPK1GBA1GJB2LGALS8LGALS3 | |
| SCHEMBL16079127 | 0.92 | MAPK1 (0.44) | MAPK1GBA1GJB2LGALS8LGALS3 | |
| SCHEMBL15508089 | 0.92 | MAPK1 (0.44) | MAPK1GBA1GJB2LGALS8LGALS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112384523-B | Ribose cationic lipids | 川斯勒佰尔公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20240374521-A1 | RIBOSE CATIONIC LIPIDS | TRANSLATE BIO INC (US) | 2024-11-14 | — | — | US | disclosed |
| US-11964051-B2 | Ribose cationic lipids | TRANSLATE BIO, INC. (US) | 2024-04-23 | — | — | US | disclosed |
| US-20220323355-A1 | Ribose Cationic Lipids | TRANSLATE BIO MA, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-3794008-A1 | RIBOSE CATIONIC LIPIDS | Translate Bio, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374521-A1 | RIBOSE CATIONIC LIPIDS | RPIA, RRM2B, SARNP | MAPK1 4446/4885GBA1 128/4885GJB2 4532/4885 |
| US-11964051-B2 | Ribose cationic lipids | RPIA, RRM2B, SARNP | MAPK1 4446/4885GBA1 128/4885GJB2 4532/4885 |
| US-20220323355-A1 | Ribose Cationic Lipids | RPIA, RRM2B, SARNP | MAPK1 4446/4885GBA1 128/4885GJB2 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.